Biological Lattice Industries Secures $1.8 Million Pre-Seed Funding to Democratize Biofabrication
Biological Lattice Industries Corp. (BLI), an innovator in biofabrication and life sciences research and development, has successfully closed a $1.8 million pre-seed investment round led by the Greek venture capital firm Uni.Fund. Alongside this funding, BLI is unveiling its all-in-one biofabrication solution: BioLoom™, an advanced multi-tool 3D bioprinter, and Loominus Studio™, a unified software platform aimed at transforming biofabrication workflows.
With R&D operations based in Greece and the U.S., BLI strives to simplify biofabrication for the global R&D community by providing automated tools that streamline the design, fabrication, and testing of biomaterials. These biomaterials are essential for a variety of biological applications, from advanced 3D cell culture systems for human biology emulation to next-generation resorbable medical devices and drug delivery systems for tissue trauma repair.
“We are excited to partner with Uni.Fund to realize our vision of democratizing biofabrication,” said Filippos Tourlomousis, Founder and CEO of BLI. “This funding will accelerate the development of our unified platform, allowing researchers to work with greater precision, reproducibility, and efficiency.”
Loominus Studio: A Unified Platform for Biofabrication
Traditional biofabrication workflows often involve coordinating multiple protocols, parameters, and instruments that lack integration. Loominus Studio™ integrates every aspect of the biofabrication workflow, from design to fabrication, allowing researchers to automate complex processes and enhance reproducibility.
“Loominus Studio sets a new standard in biofabrication, enabling labs to focus on innovation instead of integration challenges,” Tourlomousis explained. “Our goal is to make biofabrication simple and intuitive, empowering researchers to overcome technical barriers.”
BioLoom™: Advanced Bioprinting
At the heart of BLI’s tool ecosystem is BioLoom™, a versatile multi-tool extrusion-based 3D bioprinter capable of fabricating high-resolution, multi-material scaffolds and devices. With its Active Environmental Control feature, BioLoom ensures reproducibility and supports Good Manufacturing Practice (GMP) compliance, making it suitable for labs focused on commercializing life sciences innovations.
“BioLoom offers unmatched versatility and precision,” Tourlomousis added. “It meets the needs of both academic and commercial labs, pushing biofabrication beyond traditional 3D printing capabilities.”
Uni.Fund’s Role in Deep Tech Innovation
Uni.Fund, committed to supporting top deep tech startups in Europe, views BLI as a transformative player in biofabrication. “BLI is poised to revolutionize the biotech field with its vision for global biofabrication disruption,” said Katerina Pramatari, Founding Partner at Uni.Fund. “Their integrated approach combining advanced hardware and AI-powered software aligns perfectly with our mission to support groundbreaking innovations.”
Shaping the Future of Biofabrication Labs
BLI aims to establish Loominus as the industry standard for biofabrication labs, offering a continuously expanding suite of tools and features that simplify complex workflows. The investment will expedite the market introduction of BioLoom and Loominus Studio, which have already been deployed in leading academic labs through the company’s early adopter program.
About Biological Lattice Industries (BLI)
Biological Lattice Industries Corp. (BLI) is a venture-backed startup founded in 2021 with the goal of democratizing biofabrication for life sciences R&D. BLI’s platform, Loominus Studio, and its ecosystem of integrated hardware tools, including the BioLoom bioprinter, aim to revolutionize the way biomaterials are designed, fabricated, and tested.
